Mechanisms of aPL-mediated thrombosis: Effects of aPL on endothelium and platelets

Current Rheumatology Reports

Volumn 9, Issue 3, 2007, Pages 190-197

  Vega Ostertag, Mariano E ^a   Pierangeli, Silvia S ^b  

^a Instituto Fares Taie   (Argentina)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; APOLIPOPROTEIN E; ARACHIDONIC ACID; BETA2 GLYCOPROTEIN 1; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; NUCLEAR FACTOR; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPASE A2; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; THROMBOXANE; VASCULAR CELL ADHESION MOLECULE 1;

ANTIPHOSPHOLIPID SYNDROME; BLOOD VESSEL INJURY; CELL ACTIVATION; ENDOTHELIUM; ENDOTHELIUM CELL; FETUS WASTAGE; HEAT SHOCK; HUMAN; HYPOXIA; IN VIVO STUDY; ISCHEMIA; NEUTROPHIL; NONHUMAN; PHOSPHORYLATION; REPERFUSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOOD PLATELETS; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIAL CELLS; HUMANS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 34250734572     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0031-0     Document Type: Review

References (50)

1. Harris EN: Syndrome of the black swan. Br J Rheumatol 1987, 26:324-326.
2. Boey ML, Colaco CB, Gharavi AE, et al.: Thrombosis in SLE: striking associations with the presence of circulating lupus anticoagulant. Br Med J 1983, 287:1021-1023.
3. McClain MT, Arbuckle MR, Heinlen LD, et al.: The prevalence, onset and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004, 50:1226-1232.
4. Branch DW, Dudley DJ, Mitchell MD, et al.: Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990, 163:210-216.
5. Pierangeli SS, Colden-Stanfield M, Liu X, et al.: Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99:1997-2000.
6. Jankowski M, Vreys I, Wittevrongel C, et al.: Thrombogenicity of beta2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003, 101:157-162.
7. Holers VM, Girardi G, Mo L, et al.: C3 activation is required for anti-phospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211-220.
8. Salmon JE, Girardi G, Holers VM: Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002, 61:46-50.
9. • Pierangeli SS, Girardi G, Vega-Ostertag ME, et al.: Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120-2124. This paper shows that complement activation (particularly C3 and C5) mediates induction of thrombosis and activation of endothelial cells by aPL.
10. 2-GPI requires a priming factor such as bacterial LPS and is complement dependent.
11. Del Papa N, Guidali L, Sala A, et al.: Endothelial cell target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-b2glycoprotein I and induce endothelial cell activation. Arthritis Rheum 1997, 40:551-561.
12. Simantov E, LaSala J, Lo SK, et al.: Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995, 96:2211-2219.
13. Pierangeli SS, Espinola RG, Liu X, Harris EN: Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001, 88:245-250.
14. Espinola RG, Liu X, Colden-Stanfield M, et al.: E-selectin mediated pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2002, 1:843-848.
15. Kaplanski G, Cacoub P, Farnarier C, et al.: Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000, 43:55-64.
16. Williams FM, Parmar K, Hughes GR, Hunt BJ: Systemic endothelial cell markers in primary antiphospholipid syndrome. J Thromb Haemost 2000, 84:742-746.
17. Semerato N, Colucci M: Tissue factor in health and disease. Thromb Haemost 1997, 78:759-764.
18. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al.: Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997, 40:834-841.
19. Amengual O, Atsumi T, Khamashta MA, Hughes GR: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998, 79:276-281.
20. Dobado-Barrios M, Lopez-Perrara C, Velasco F, et al.: Increased levels of TF mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999, 82:1578-1582.
21. Zhou H, Woldberg AS, Roubey RA: Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004, 104:2353-2358.
22. Forastiero RR, Martinuzzo ME, De Larranaga G: Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprous related antiphospholipid antibodies. Lupus 2005, 14:129-136.
23. Firestein GS: NF-kappaB: Holy grail for rheumatoid arthritis. Arthritis Rheum 2004, 50:2381-2386.
24. Cohen P: The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol 1997, 7:353-358.
25. Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteiz B, et al.: NF-kappaB is an essential intermediate in the activation of endothelial cells by anti-beta2glycoprotein I antibodies. Thromb Haemost 2002; 88:851-857.
26. Bohgaki M, Atsumi T, Yamashita Y, et al.: The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2glycoprotein I antibodies. Int Immunol 2004, 16:1632-1641.
27. Vega-Ostertag M, Casper K, Swerlick R, et al.: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52:1545-1554.
28. Simoncini S, Sapet C, Camoin-Jau L, et al.: Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 2004, 17:489-500.
29. López-Pedrera C, Buendía P, Cuadrado MJ, et al.: Antiphopholipid antibodies from patients with the antiphospholipid syndrome induce tissue factor expression through the simultaneous activation of NF-KappaB/Rel proteins via p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006, 54:301-311.
30. Pierangeli SS, Vega-Ostertag ME, Liu X: An inhibitor of p38 mitogen-activated protein kinase abrogates procoagulant and proinflammatory effects of antiphospholipid antibodies in vivo [abstract]. Blood 2005, 106:43a.
31. Del Papa N, Sheng YH, Raschi E, et al.: Human beta2glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipids binding and offers epitopes for anti-beta2glycoprotein I antibodies. J Immunol 1998, 160:5572-5578.
32. Vega Ostertag M, Liu X, Henderson V, Pierangeli SS: A peptide that mimics the Vth region of beta2glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 2006, 15:358-365.
33. Zhang J, McCrae KR: Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005, 105:1964-1969.
34. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al.: Auto-antibodies against the fibrinolytic receptor, annexin A2, in antiphospholipid syndrome. Blood 2006, 107:4375-4382.
35. Di Simone N, Raschi E, Testoni C, et al.: Pathogenic role of anti-b2glycoprotein I antibodies in antiphospholipid associated fetal loss: characterization of b2glycoprotein I binding to trophoblasts cells and functional effects of anti-b2glycoprotein I antibodies in vitro. Ann Rheum Dis 2005, 64:462-467.
36. Di Simone N, Meroni PL, Del Papa N, et al.: Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2glycoprotein I. Arthritis Rheum 2000, 43:140-151.
37. Raschi E, Testoni C, Bosisio D, et al.: Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 101:3495-3500.
38. • Pierangeli SS, Vega-Ostertag ME, Raschi E, et al.: Toll-like receptor 4 is involved in antiphospholipid-mediated thrombosis: In vivo studies. Ann Rheum Dis 2007, Epub ahead of print. This study demonstrates the involvement of TLR4 in aPL-mediated effects in vivo.
39. Wojta J, Kaun C, Zorn G, et al.: C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002, 100:517-523.
40. Carbone J, Orera M, Rodriguez-Mahou M, et al.: Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus 1999, 8:274-278.
41. Munakata Y, Saito T, Matsuda K, et al.: Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 2000, 83:728-731.
42. Davis WD, Brey RL: Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol 1992, 10:455-460.
43. Khamashta MA, Harris EN, Gharavi AE, et al.: Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988, 47:849-854.
44. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN: Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995, 73:529-534.
45. Lutters BC, Derksen RH, Tekelenburg WL, et al.: Dimers of beta2 glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003, 278:33831-33838.
46. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN: Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002, 87:518-522.
47. Forastiero R, Martinuzzo M, Carreras LO, Maclouf J: Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998, 79:42-45.
48. Robbins DL, Leung S, Miller-Blair DJ, ZIboh V: Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998, 25:51-56.
49. Vega-Ostertag M, Harris EN, Pierangeli SS: Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004, 50:2911-2919.
50. 2-GPI complex can directly bind GPIb on platelets and induce their activation.